Active Not Recruiting PHASE4 INTERVENTIONAL 2-arm NCT05537948

Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients (PINTL)

Sponsor: National Medical Research Center for Therapy and Preventive Medicine

Conditions Dyslipidemias Hydroxymethylglutaryl-CoA Reductase Inhibitors Hyperlipidemias Immunosuppression Liver Transplant Disorder Statins

Interventions PCSK9 inhibitor Pitavastatin

Updated 7 times since 2022 Last updated: Jan 21, 2025 Started: Oct 1, 2021 Primary completion: Jan 31, 2024 Completion: Jan 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05537948, this PHASE4 trial focuses on Dyslipidemias and Hydroxymethylglutaryl-CoA Reductase Inhibitors and remains ongoing. Sponsored by National Medical Research Center for Therapy and Preventive Medicine, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE4
Feb 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE4

Status: Recruiting → Active Not Recruiting
Sep 2024 — Feb 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE4

▶ Show 2 earlier versions

Jan 2024 — Mar 2024 [monthly]

Recruiting PHASE4
Sep 2022 — Jan 2024 [monthly]

Recruiting PHASE4

First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Medical Research Center for Therapy and Preventive Medicine

Data source: National Medical Research Center for Therapy and Preventive Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Moscow, Russia